Urothelial carcinoma: the evolving landscape of immunotherapy for patients with advanced disease

References

• SiegelRLMillerKDJemalACancer statistics, 2017CA Cancer J Clin201767173028055103
   PubMed Web of Science ®Google Scholar
• National Comprehensive Cancer NetworkClinical Practice Guidelines in Oncology: Bladder cancer, version 52017 Available from: NCCN.orgAccessed December 13, 2017
   Google Scholar
• ParkJCCitrinDEAgarwalPKApoloABMultimodal management of muscle invasive bladder cancerCurr Probl Cancer20143838010825087173
   PubMed Web of Science ®Google Scholar
• Survival rates for bladder cancerAmerican Cancer Society Available from: http://www.cancer.org/cancer/bladdercancer/detailedguide/bladder-cancer-survival-ratesAccessed May 23, 2016
   Google Scholar
• KirkwoodJMButterfieldLHTarhiniAAZarourHKalinskiPFerroneSImmunotherapy of cancer in 2012CA Cancer J Clin201262530935522576456
   PubMed Web of Science ®Google Scholar
• IntlekoferAMThompsonCBAt the bench: preclinical rationale for CTLA-4 and PD-1 blockade as cancer immunotherapyJ Leukoc Biol2013941253923625198
   PubMed Web of Science ®Google Scholar
• LogothetisCJDexeusFHFinnLA prospective randomized trial comparing MVAC and CISCA chemotherapy for patients with metastatic urothelial tumorsJ Clin Oncol199086105010552189954
   PubMed Web of Science ®Google Scholar
• TannockIGospodarowiczMConnollyJJewettMM-VAC (methotrexate, vinblastine, doxorubicin, and cisplatin) chemotherapy for transitional cell carcinoma: the Princess Margaret Hospital experienceJ Urol19891422 Pt 12892922746745
   PubMed Web of Science ®Google Scholar
• MooreMJIscoeNTannockIFA phase II study of methotrexate, vinblastine, doxorubicin, and cisplatin plus recombinant human granulocyte-macrophage colony stimulating factors in patients with advanced transitional cell carcinomaJ Urol19931504113111348371371
   PubMed Web of Science ®Google Scholar
• SternbergCNde MulderPSchornagelJHEORTC Genito-Urinary Cancer GroupSeven year update of an EORTC phase III trial of high-dose intensity M-VAC chemotherapy and G-CSF versus classic M-VAC in advanced urothelial tract tumoursEur J Cancer2006421505416330205
   PubMed Web of Science ®Google Scholar
• von der MaaseHHansenSWRobertsJTGemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III studyJ Clin Oncol200018173068307711001674
   PubMed Web of Science ®Google Scholar
• GalskyMDChenGJOhWKComparative effectiveness of cisplatin-based and carboplatin-based chemotherapy for treatment of advanced urothelial carcinomaAnn Oncol201223240641021543626
   PubMed Web of Science ®Google Scholar
• GalskyMDHahnNMRosenbergJTreatment of patients with metastatic urothelial cancer “unfit” for cisplatin-based chemotherapyJ Clin Oncol201129172432243821555688
   PubMed Web of Science ®Google Scholar
• De SantisMBellmuntJMeadGRandomized phase II/III trial assessing gemcitabine/carboplatin and methotrexate/carboplatin/vinblastine in patients with advanced urothelial cancer who are unfit for cisplatin-based chemotherapy: EORTC study 30986J Clin Oncol201230219119922162575
   PubMed Web of Science ®Google Scholar
• SternbergCNCalabroFPizzocaroGMariniLSchnetzerSSellaAChemotherapy with an every 2-week regimen of gemcitabine and paclitaxel in patients with transitional cell carcinoma who have received prior cisplatin-based therapyCancer200192122993299811753976
   PubMed Web of Science ®Google Scholar
• MeluchAAGrecoFABurrisHA3rdPaclitaxel and gemcitabine chemotherapy for advanced transitional-cell carcinoma of the urothelial tract: a phase II trial of the Minnie pearl cancer research networkJ Clin Oncol200119123018302411408496
   PubMed Web of Science ®Google Scholar
• LiJJuliarBYiannoutsosCWeekly paclitaxel and gemcitabine in advanced transitional-cell carcinoma of the urothelium: a phase II Hoosier Oncology Group studyJ Clin Oncol20052361185119115718315
   PubMed Web of Science ®Google Scholar
• CalabroFLorussoVRosatiGGemcitabine and paclitaxel every 2 weeks in patients with previously untreated urothelial carcinomaCancer2009115122652265919396817
   PubMed Web of Science ®Google Scholar
• GitilitzBJBakerCChapmanYA phase II study of gemcitabine and docetaxel therapy in patients with advanced urothelial carcinomaCancer2003989186314584068
   PubMed Web of Science ®Google Scholar
• ArdavanisATryfonopoulosDAlexopoulosAKandylisCLainakisGRigatosGGemcitabine and docetaxel as first-line treatment for advanced urothelial carcinoma: a phase II studyBr J Cancer200592464565015685232
   PubMed Web of Science ®Google Scholar
• WitteRSElsonPBonoBEastern Cooperative Oncology Group phase II trial of ifosfamide in the treatment of previously treated advanced urothelial carcinomaJ Clin Oncol19971525895939053481
   PubMed Web of Science ®Google Scholar
• DreicerRGustinDMSeeWAWilliamsRDPaclitaxel in advanced urothelial carcinoma: its role in patients with renal insufficiency and as salvage therapyJ Urol19961565160616088863548
   PubMed Web of Science ®Google Scholar
• RothBJDreicerREinhornLHSignificant activity of paclitaxel in advanced transitional-cell carcinoma of the urothelium: a phase II trial of the Eastern Cooperative Oncology GroupJ Clin Oncol19941211226422707525883
   PubMed Web of Science ®Google Scholar
• de WitRKruitWHStoterGde BoerMKergerJVerweijJDocetaxel (Taxotere): an active agent in metastatic urothelial cancer; results of a phase II study in non-chemotherapy-pretreated patientsBr J Cancer19987810134213459823976
   PubMed Web of Science ®Google Scholar
• McCaffreyJAHiltonSMazumdarMPhase II trial of docetaxel in patients with advanced or metastatic transitional-cell carcinomaJ Clin Oncol1997155185318579164195
   PubMed Web of Science ®Google Scholar
• LorussoVPolleraCFAntimiMA phase II study of gemcitabine in patients with transitional cell carcinoma of the urinary tract previously treated with platinum. Italian Co-operative Group on Bladder CancerEur J Cancer1998348120812129849481
   PubMed Web of Science ®Google Scholar
• MooreMJTannockIFErnstDSHuanSMurrayNGemcitabine: a promising new agent in the treatment of advanced urothelial cancerJ Clin Oncol19971512344134459396395
   PubMed Web of Science ®Google Scholar
• BellmuntJvon der MaaseHMeadGMRandomized phase III study comparing paclitaxel/cisplatin/gemcitabine and gemcitabine/cisplatin in patients with locally advanced or metastatic urothelial cancer without prior systemic therapy: EORTC Intergroup Study 30987J Clin Oncol201230101107111322370319
   PubMed Web of Science ®Google Scholar
• GallagherDJMilowskyMIBajorinDFAdvanced bladder cancer: status of first-line chemotherapy and the search for active agents in the second-line settingCancer200811361284129318629841
   PubMed Web of Science ®Google Scholar
• SweeneyCJRothBJKabbinavarFFPhase II study of pemetrexed for second-line treatment of transitional cell cancer of the urotheliumJ Clin Oncol200624213451345716849761
   PubMed Web of Science ®Google Scholar
• KoYJCanilCMMukherjeeSDNanoparticle albumin-bound paclitaxel for second-line treatment of metastatic urothelial carcinoma: a single group, multicentre, phase 2 studyLancet Oncol20131487697623706985
   PubMed Web of Science ®Google Scholar
• BellmuntJTheodoreCDemkovTPhase III trial of vinflunine plus best supportive care compared with best supportive care alone after a platinum-containing regimen in patients with advanced transitional cell carcinoma of the urothelial tractJ Clin Oncol200927274454446119687335
   PubMed Web of Science ®Google Scholar
• PetrylakDPde WitRChiKNRANGE study investigatorsRamucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): a randomized, double-blind, phase 3 trialLancet2017390101092266227728916371
   PubMed Web of Science ®Google Scholar
• GlaserAPFantiniDShilatifardASchaefferEMMeeksJJThe evolving genomic landscape of urothelial carcinomaNat Rev Urol201714421522928169993
   PubMed Web of Science ®Google Scholar
• RajasagiMShuklaSAFritschEFSystematic identification of personal tumor-specific neoantigens in chronic lymphocytic leukemiaBlood2014124345346224891321
   PubMed Web of Science ®Google Scholar
• LawrenceMSStojanovPPolakPMutational heterogeneity in cancer and the search for new cancer-associated genesNature2013499745721421823770567
   PubMed Web of Science ®Google Scholar
• BrownSDWarrenRLGibbEANeo-antigens predicted by tumor genome meta-analysis correlate with increased patient survivalGenome Res201424574375024782321
   PubMed Web of Science ®Google Scholar
• HerbstRSSoriaJCKowanetzMPredictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patientsNature2014515752856356725428504
   PubMed Web of Science ®Google Scholar
• RosenbergJEHoffman-CensitsJPowlesTAtezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicenter, phase 2 trialLancet2016387100311909192026952546
   PubMed Web of Science ®Google Scholar
• NingYMSuzmanDMaherVEFDA approval summary: atezolizumab for the treatment of patients with progressive advanced urothelial carcinoma after platinum-containing chemotherapyOncologist201722674374928424325
   PubMed Web of Science ®Google Scholar
• BalarAVGalskyMDRosenbergJEAtezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicenter, phase 2 trialLancet201738910064677627939400
   PubMed Web of Science ®Google Scholar
• A Study of Atezolizumab Compared with Chemotherapy in Participants with Locally Advanced or Metastatic Urothelial Bladder Cancer [IMvigor211] Available from: https://clinicaltrials.gov/ct2/show/results/NCT02302807Accessed December 13, 2017
   Google Scholar
• Genentech Provides Update on Phase III Study of Tecentriq (Atezolizumab) In People with Previously Treated Advanced Bladder Cancer Available from: https://www.gene.com/media/press-releases/14665/2017-05-09/genentech-provides-update-on-phase-iii-sAccessed May 9, 2017
   Google Scholar
• BellmuntJde WitRVaughnDJKEYNOTE-045 InvestigatorsPembrolizumab as second-line therapy for advanced urothelial carcinomaN Engl J Med2017376111015102628212060
   PubMed Web of Science ®Google Scholar
• BalarAVCastellanoDEO’DonnellPHPembrolizumab as first-line therapy in cisplatin-ineligible advanced urothelial cancer: results from the total KEYNOTE-052 study populationJ Clin Oncol2017352
   Google Scholar
• SharmaPCallahanMKBonoPNivolumab monotherapy in recurrent metastatic urothelial carcinoma (CheckMate 032):a multicenter, open-label, two-stage, multi-arm, phase 1/2 trialLancet Oncol201617111590159827733243
   PubMed Web of Science ®Google Scholar
• SharmaPRetzMSiefker-RadtkeANivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275):a multicenter, single-arm, phase 2 trialLancet Oncol201718331232228131785
   PubMed Web of Science ®Google Scholar
• IbrahimRStewartRShalabiAPD-L1 blockade for cancer treatment:MEDI4736Semin Oncol201542347448325965366
   PubMed Web of Science ®Google Scholar
• PowlesTO’DonnellPHMassardCEfficacy and Safety of durvalumab in locally advanced or metastatic urothelial carcinoma: updated results from a Phase ½ Open-label StudyJAMA Oncol201739e17241128817753
   PubMed Web of Science ®Google Scholar
• ApoloABInfanteJRBalmanoukianAAvelumab, an anti-programmed death-ligand 1 antibody, in patients with refractory metastatic urothelial carcinoma: results from a multicenter, Phase Ib StudyJ Clin Oncol201735192117212428375787
   PubMed Web of Science ®Google Scholar
• SzabadosBvan DijkNTangYZResponse rate to chemotherapy after immune checkpoint inhibition in metastatic urothelial cancerEur Urol Epub2017913
   Web of Science ®Google Scholar
• LawrenceMSStonjanovPMermelCHDiscovery and saturation analysis of cancer genes across 21 tumour typesNature2014505748449550124390350
   PubMed Web of Science ®Google Scholar
• RobertsSALawrenceMSKlimczakLJAn APOBEC cytidine deaminase mutagenesis pattern is widespread in human cancersNat Genet201345997097623852170
   PubMed Web of Science ®Google Scholar
• RobertsonAGKimJAl-AhmadieHComprehensive molecular characterization of muscle-invasive bladder cancerCell2017171354055628988769
   PubMed Web of Science ®Google Scholar
• SeilerRAshabHADErhoNImpact of molecular subtypes in muscle-invasive bladder cancer of predicting survival after neoadjuvant chemotherapyEur Urol201772454455428390739
   PubMed Web of Science ®Google Scholar